Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Parkinson's disease, primates, and gene therapy: vive la différence?

Literature DB >> 21322013

Parkinson's disease, primates, and gene therapy: vive la différence?

Travis B Lewis, David G Standaert.

Abstract

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 21322013 PMCID： PMC3079954 DOI： 10.1002/mds.23544

Source DB: PubMed Journal: Mov Disord ISSN： 0885-3185 Impact factor: 10.338

× No keyword cloud information.

13 in total

1. Target validation: the Parkinson disease perspective.

Authors: David G Standaert; Talene A Yacoubian
Journal: Dis Model Mech Date: 2010 May-Jun Impact factor: 5.758

Review 2. Axonal transport defects in neurodegenerative diseases.

Authors: Gerardo A Morfini; Matthew Burns; Lester I Binder; Nicholas M Kanaan; Nichole LaPointe; Daryl A Bosco; Robert H Brown; Hannah Brown; Ashutosh Tiwari; Lawrence Hayward; Julia Edgar; Klaus-Armin Nave; James Garberrn; Yuka Atagi; Yuyu Song; Gustavo Pigino; Scott T Brady
Journal: J Neurosci Date: 2009-10-14 Impact factor: 6.167

Review 3. Design of clinical trials of gene therapy in Parkinson disease.

Authors: Travis B Lewis; David G Standaert
Journal: Exp Neurol Date: 2007-08-31 Impact factor: 5.330

4. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

Authors: Jeffrey H Kordower; Christopher D Herzog; Biplob Dass; Roy A E Bakay; James Stansell; Mehdi Gasmi; Raymond T Bartus
Journal: Ann Neurol Date: 2006-12 Impact factor: 10.422

5. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.

Authors: Jessie L St Martin; Jochen Klucken; Tiago F Outeiro; Paul Nguyen; Christine Keller-McGandy; Ippolita Cantuti-Castelvetri; Tom N Grammatopoulos; David G Standaert; Bradley T Hyman; Pamela J McLean
Journal: J Neurochem Date: 2007-01-04 Impact factor: 5.372

6. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.

Authors: John T Slevin; Don M Gash; Charles D Smith; Greg A Gerhardt; Richard Kryscio; Himachandra Chebrolu; Ashley Walton; Renee Wagner; A Byron Young
Journal: J Neurosurg Date: 2007-04 Impact factor: 5.115

7. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

Authors: William J Marks; Jill L Ostrem; Leonard Verhagen; Philip A Starr; Paul S Larson; Roy Ae Bakay; Robin Taylor; Deborah A Cahn-Weiner; A Jon Stoessl; C Warren Olanow; Raymond T Bartus
Journal: Lancet Neurol Date: 2008-04-02 Impact factor: 44.182

8. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.

Authors: Christopher D Herzog; Lamar Brown; Dawn Gammon; Brian Kruegel; Richard Lin; Alistair Wilson; Ariadne Bolton; Marie Printz; Mehdi Gasmi; Kathie M Bishop; Jeffrey H Kordower; Raymond T Bartus
Journal: Neurosurgery Date: 2009-04 Impact factor: 4.654

9. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.

Authors: Xiaomin Su; Adrian P Kells; Eric J Huang; Han S Lee; Piotr Hadaczek; Janine Beyer; John Bringas; Philip Pivirotto; Janine Penticuff; Jamie Eberling; Howard J Federoff; John Forsayeth; Krystof S Bankiewicz
Journal: Hum Gene Ther Date: 2009-12 Impact factor: 5.695